This past weekend, Dr. Alex Jaeger gave an oral presentation at the Society of Immunotherapy in Cancer conference in San Diego. The talk focused on our lab's work evaluating MHC-II antigen presentation in vivo to identify targets for immunotherapy.
"What my group has done is pioneer the use of mouse models to actually understand the mechanisms that influence what peptides are being presented in the context of the tumor microenvironment," Dr. Jaeger explains. This novel method of tumor specific antigen discovery will allow for major developments in the field of immunopeptidomics.
"Our work has already gained insights into what peptides are being presented in various contexts that can ultimately be leveraged to improve vaccine design or adoptive cell therapies."
To read the abstract, click here.
Comments